Sumitomo Mitsui Trust Group Boosts Stake in Bio-Techne

Institutional investor increases ownership in biotech company by 0.5% in Q4 2025.

Apr. 13, 2026 at 10:22am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a collection of sleek, polished laboratory equipment and research tools arranged artfully on a clean, monochromatic background, conceptually representing the precision and innovation of Bio-Techne's product portfolio.Institutional investors see long-term value in Bio-Techne's specialized life sciences tools and reagents.Minneapolis Today

Sumitomo Mitsui Trust Group Inc. grew its stake in Bio-Techne Corp (NASDAQ:TECH) by 0.5% in the fourth quarter, according to the company's latest SEC filing. The fund now owns 2,368,162 shares of the biotechnology company's stock, representing a 1.52% ownership position valued at $139,272,000.

Why it matters

This investment signals continued institutional confidence in Bio-Techne's growth potential as a leading provider of life sciences research tools and reagents. The stock has seen volatility in the past year, making strategic stake increases by major investors noteworthy.

The details

Sumitomo Mitsui Trust Group added 12,544 shares of Bio-Techne in Q4 2025, increasing its total position to 2,368,162 shares. This represents a 0.5% increase in the fund's ownership stake, which was previously 1.47%. Other major institutional investors in Bio-Techne include Wellington Management, Massachusetts Financial Services, and Invesco.

  • Sumitomo Mitsui Trust Group filed its Q4 2025 13F report on April 13, 2026.
  • The reported stake increase occurred during the three-month period ending December 31, 2025.

The players

Sumitomo Mitsui Trust Group Inc.

A major Japanese financial services group that provides asset management, banking, and real estate services globally.

Bio-Techne Corp

A global life sciences company that develops and manufactures high-quality reagents, instruments, and services for research, diagnostic, and bioprocessing markets.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if other major institutions follow Sumitomo Mitsui Trust Group's lead and increase their stakes in Bio-Techne in the coming quarters.

The takeaway

Bio-Techne's diversified life sciences product portfolio and strong market position continue to attract investment from large institutional funds, signaling the company's long-term growth prospects despite recent stock price volatility.